Search


	Podcast:		The Bio Report
	Episode:		Free Speech Ruling May Force FDA to Rethink Off-Label Marketing
	Category:		Business
	Duration:		00:20:16
	Publish Date:		2015-08-14 11:27:38
	Description:		Earlier this month in a preemptive challenge from Amarin Pharma against the U.S. Food and Drug Administration a federal judge ruled that the FDA cannot prohibit a drugmaker from promoting the off-label use of a drug if it does so through the dissemination of truthful and non-misleading information. The decision about the First Amendment Rights of a pharmaceutical company is seen as a significant ruling in a long-standing battle between the agency and the industry that has played out over the past 20 years. We spoke to John Kamp, executive director of the Coalition for Healthcare Communication, about the case, the issues behind it, and its implications for how the industry and agency will act going forward.
	Total Play:		0

Some more Podcasts by Levine Media Group

600+ Episodes

The Bio Repo ..